Stocktoria
Fresenius Medical Care AG FMS
Fresenius Medical Care AG (FMS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend (safety: safe).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.59 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2025-09-02 | UBS | Sell (down) |
| 2025-05-12 | Truist Securities | Hold (main) |
| 2025-01-06 | Truist Securities | Hold (main) |
| 2024-10-07 | Truist Securities | Hold (main) |
| 2024-07-31 | Truist Securities | Hold (main) |
| 2024-05-15 | Truist Securities | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.085 |
| Retained earnings / assets | 0.328 |
| EBIT / assets | 0.098 |
| Equity / liabilities | 0.805 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FMS | Fresenius Medical Care AG | 5/9 | 3.13 | — | +5.9% |
| DVA | DAVITA INC. | 6/9 | 1.03 | 18.7 | +6.5% |
| AGL | agilon health, inc. | 2/9 | -7.3 | — | -2.1% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
FAQ
Is FMS financially healthy?
Fresenius Medical Care AG's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does FMS pay a dividend, and is it safe?
Yes. Fresenius Medical Care AG pays a dividend with a -22.3% payout ratio, rated “safe” for safety.
How profitable is FMS?
In FY2016, Fresenius Medical Care AG had a return on equity of 10.9%.
Is FMS overvalued or undervalued?
Fresenius Medical Care AG trades at about 5.8× trailing earnings — below its 10-year norm (10-year range 9.1×–13.2×, median 10.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for FMS?
The average Wall-Street price target for Fresenius Medical Care AG is $25.38, about 7.0% above the recent price, from 6 analysts.
Is FMS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Fresenius Medical Care AG: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2016-12-31. Facts plus Stocktoria's own computed scores — not investment advice.